ArticleOncoimmunology2020
A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer.
Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 45 citations in OpenAlex.
- Targeting regulatory T cells in the prostate cancer microenvironment: From mechanisms to therapeutics (Review).Molecular medicine reports · 2026Review
- Combined SNPs sequencing and allele specific proteomics capture reveal functional causality underpinning the 2p25 prostate cancer susceptibility locus.Nature communications · 2025Article
- Characteristics of Oxidative Phosphorylation-Related Subtypes and Construction of a Prognostic Signature in Ovarian Cancer.Current gene therapy · 2025Article
- Development of a prostate cancer biochemical recurrence risk signature using machine learning and motor protein-related genes.PloS one · 2025Article
- Utilizing a novel model of PANoptosis-related genes for enhanced prognosis and immune status prediction in kidney renal clear cell carcinoma.Apoptosis : an international journal on programmed cell death · 2024Article
- The 15-year national trends of urinary cancers incidence among Iranian men and women; 2005-2020.International journal for equity in health · 2024Article
- Article
- Systematic review and integrated analysis of prognostic gene signatures for prostate cancer patients.Discover oncology · 2023Article
- Integrative analysis of the SOX family-related prognostic signature and immunological infiltration in prostate cancer.Translational cancer research · 2023Article
- Crafting a Personalized Prognostic Model for Malignant Prostate Cancer Patients Using Risk Gene Signatures Discovered through TCGA-PRAD Mining, Machine Learning, and Single-Cell RNA-Sequencing.Diagnostics (Basel, Switzerland) · 2023Article
- Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer.Journal of cancer research and clinical oncology · 2023Article
- Clinical Significance and Tumor Microenvironment Characterization of a Novel Immune-Related Gene Signature in Bladder Cancer.Journal of clinical medicine · 2023Article
- Nanomedicine for Combination Urologic Cancer Immunotherapy.Pharmaceutics · 2023Review
- Epigenetic modulation and prostate cancer: Paving the way for NK cell anti-tumor immunity.Frontiers in immunology · 2023Review
- Therapeutic implications for localized prostate cancer by multiomics analyses of the ageing microenvironment landscape.International journal of biological sciences · 2023Article
- HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma.PeerJ · 2023Article
- Multimolecular characteristics of cell-death related hub genes in human cancers: a comprehensive pan-cancer analysis.Cell cycle (Georgetown, Tex.) · 2022Article
- Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.Cancer medicine · 2022Article
- Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia.Metabolites · 2022Review
- Prostate Cancer Secretome and Membrane Proteome fromInternational journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is one of the most common malignancies in male. We aim to establish a novel gene signature for immune infiltration and outcome (biochemical recurrence (BCR) and overall survival (OS)) of patients with prostate cancer (PCa) to augment Gleason patterns for evaluating prognosis and managing patients undergoing radical prostatectomy (RP). Combined with our microarray data and the Cancer Genome Atlas Project (TCGA) database (discovery set), we identified a six-gene signature. The Gene Expression Omnibus (GEO) database served as the test set. The databases of Fudan University Shanghai Cancer Center (FUSCC) and Third Affiliated Hospital of Nantong University (TAHNU) served as an external validation set. Immunohistochemistry was used to investigate the relationship between risk groups and the immune infiltrate. We identified a six-gene signature to predict immune cell infiltration and outcome of PCa patients. The AUC values used to predict early BCR in the discovery, test, FUSCC, and TAHNU sets were 0.73, 0.76, 0.72, and 0.81, respectively. Low-risk score patients in each dataset experienced significantly longer OS (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.